Pfizer's $5.4B Deal To Acquire Drugmaker Faces Investor Suit
Global Blood Therapeutics Inc. investors have challenged Pfizer's $5.4 billion plan to acquire the sickle cell-drug company, claiming that GBT's top brass made incomplete and misleading disclosures in an attempt to...To view the full article, register now.
Already a subscriber? Click here to view full article